摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-[4-(thiophen-2-yl)-1,3-thiazol-2-yl]-9H-xanthene-9-carboxamide

中文名称
——
中文别名
——
英文名称
N-[4-(thiophen-2-yl)-1,3-thiazol-2-yl]-9H-xanthene-9-carboxamide
英文别名
N-(4-thiophen-2-yl-1,3-thiazol-2-yl)-9H-xanthene-9-carboxamide
N-[4-(thiophen-2-yl)-1,3-thiazol-2-yl]-9H-xanthene-9-carboxamide化学式
CAS
——
化学式
C21H14N2O2S2
mdl
MFCD02372864
分子量
390.5
InChiKey
RRMRIQLYFFGEFO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.7
  • 重原子数:
    27
  • 可旋转键数:
    3
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.05
  • 拓扑面积:
    108
  • 氢给体数:
    1
  • 氢受体数:
    5

文献信息

  • AROMATIC 5-MEMBERED HETEROCYCLIC DERIVATIVE HAVING TRPV4-INHIBITING ACTIVITY
    申请人:Shionogi & Co., Ltd.
    公开号:US20150038483A1
    公开(公告)日:2015-02-05
    The present invention is related to a compound represented by formula (I) wherein R 1 is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted aromatic carbocyclyl, or the like; X is —N(R 3 )—, —O—, or —S—; Y is ═C(R 4 )—, or ═N—; Z is —N(R 7 )—, —O—, or —S—; R 2 is substituted or unsubstituted alkyloxy, or the like, or a group represented by the following formula: —(CR 2a R 2b ) n —R 2c , wherein R 2a is each independently a hydrogen atom, halogen, or the like; R 2b is each independently a hydrogen atom, halogen, or the like; R 2a and R 2b which are attached to the same carbon atom may be taken together to form oxo, a substituted or unsubstituted non-aromatic carbocycle, or the like; two of R 2a which are attached to the adjacent carbon atoms and/or two of R 2b which are attached to the adjacent carbon atoms may be taken together to form a bond; R 2c is substituted or unsubstituted aromatic carbocyclyl, or the like; n is an integer from 1 to 3; R 3 and R 7 are each independently a hydrogen atom, substituted or unsubstituted alkyl, or the like; R 4 and R 5 are each independently a hydrogen atom, halogen, substituted or unsubstituted alkyl, or the like; R 6 is a hydrogen atom, halogen, substituted or unsubstituted alkyl, or the like, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising thereof.
    本发明涉及一种由式(I)表示的化合物,其中R1是氢原子,取代或未取代的烷基,取代或未取代的芳香环烷基等;X是—N(R3)—,—O—或—S—;Y是═C(R4)—或═N—;Z是—N(R7)—,—O—或—S—;R2是取代或未取代的烷氧基等,或以下式表示的基团:—(CR2aR2b)n—R2c,其中R2a分别是氢原子,卤素等;R2b分别是氢原子,卤素等;附在同一碳原子上的R2a和R2b可以共同形成氧化物,取代或未取代的非芳香环烷基等;附在相邻碳原子上的两个R2a和/或附在相邻碳原子上的两个R2b可以共同形成键;R2c是取代或未取代的芳香环烷基等;n是1到3的整数;R3和R7分别是氢原子,取代或未取代的烷基等;R4和R5分别是氢原子,卤素,取代或未取代的烷基等;R6是氢原子,卤素,取代或未取代的烷基等,或其药学上可接受的盐,或包含其的药物组合物。
  • AROMATIC HETEROCYCLIC FIVE-MEMBERED RING DERIVATIVE HAVING TRPV4 INHIBITORY ACTIVITY
    申请人:Shionogi & Co., Ltd.
    公开号:EP2832731A1
    公开(公告)日:2015-02-04
    The present invention is related to a compound represented by formula (I) wherein R1 is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted aromatic carbocyclyl, or the like; X is -N(R3)-, -O-, or -S-; Y is =C(R4)-, or =N-; Z is -N(R7)-, -O-, or -S-; R2 is substituted or unsubstituted alkyloxy, or the like, or a group represented by the following formula: -(CR2aR2b)n-R2c, wherein R2a is each independently a hydrogen atom, halogen, or the like; R2b is each independently a hydrogen atom, halogen, or the like; R2a and R2b which are attached to the same carbon atom may be taken together to form oxo, a substituted or unsubstituted non-aromatic carbocycle, or the like; two of R2a which are attached to the adjacent carbon atoms and/or two of R2b which are attached to the adjacent carbon atoms may be taken together to form a bond; R2c is substituted or unsubstituted aromatic carbocyclyl, or the like; n is an integer from 1 to 3; R3 and R7 are each independently a hydrogen atom, substituted or unsubstituted alkyl, or the like; R4 and R5 are each independently a hydrogen atom, halogen, substituted or unsubstituted alkyl, or the like; R6 is a hydrogen atom, halogen, substituted or unsubstituted alkyl, or the like, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising thereof.
    本发明涉及一种由式(I)表示的化合物 其中 R1 是氢原子、取代或未取代的烷基、取代或未取代的芳香族羰基或类似物;X 是-N(R3)-、-O-或-S-;Y 是=C(R4)-、或=N-;Z 是-N(R7)-、-O-或-S-; R2 是取代或未取代的烷氧基,或类似物,或下式所代表的基团:-(CR2aR2b)n-R2c,其中 R2a 各自独立地为氢原子、卤素或类似物;R2b 各自独立地为氢原子、卤素或类似物;连接到相同碳原子上的 R2a 和 R2b 可一起形成氧代、取代或未取代的非芳香族碳环或类似物;与相邻碳原子相连的两个 R2a 和/或与相邻碳原子相连的两个 R2b 可结合在一起形成键; R2c 是取代或未取代的芳香族碳环或类似物; n 是 1 到 3 的整数; R3 和 R7 各自独立地为氢原子、取代或未取代的烷基或类似物; R4 和 R5 各自独立地为氢原子、卤素、取代或未取代的烷基或类似物; R6 是氢原子、卤素、取代或未取代的烷基或类似物、 或其药学上可接受的盐,或由其组成的药物组合物。
  • US9499533B2
    申请人:——
    公开号:US9499533B2
    公开(公告)日:2016-11-22
查看更多